ATS 2019 Virtual Final Program

122 Facilitating Factors for Home and Hospice Deaths in Interstitial Lung Disease (ILD) Patients/ N. Archibald, Edmonton, Canada, p.A5629 123 Assessment of a Cough Visual Analogue Scale with Validated Instruments in Patients with Idiopathic Pulmonary Fibrosis/ S.S. Jacobs, K.K. Morris, J.J. Mooney, R. Raj, J.J. Swigris, Stanford, CA, p.A5630 124 Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and the Potential Future Role of Anti-fibrotics* in a Treatment Paradigm for SSc-ILD: A Delphi Consensus Study/ F.F. Rahaghi, M.E. Strek, B.D. Southern, R. Saggar, V. Hsu, M.D. Mayes, R.M. Silver, V. Steen, R.T. Domsic, I.O. Rosas, R.J. Kaner, N.Y. Bhatt, K.R. Flaherty, N. Gupta, F.J. Martinez, L.E. Morrow, N. Patel, O.A. Shlobin, E.J. Bernstein, F.V. Castelino, L. Chung, B. Kahaleh, T. Moua, E.R. Volkmann, D. Khanna, Chicago, IL, p.A7445 125 Prognostic Significance of Macrophage-Mannose Receptor, CD206, in Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Interstitial Lung Disease/ Y. Suzuki, T. Fujisawa, H. Hozumi, H. Yasui, M. Karayama, K. Furuhashi, N. Enomoto, Y. Nakamura, N. Inui, T. Suda, Hamamatsu, Japan, p.A7446 CLINICAL POSTER DISCUSSION SESSION C102 COPD: RISK PREDICTION AND PROGNOSIS 2:15 p.m. - 4:15 p.m. KBHCCD Room C141/C143/C149 (Level 1) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: W.W. Labaki, MD, Ann Arbor, MI K.F. Rabe, MD, PhD, Grosshansdorf, Germany 201 Heterogeneity of Eosinophilic and Type-2 Inflammation in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)/ W. Tew, X. Yang, Y. Cao, D. Choy, S. Christenson, I. Barjaktarevic, E.R. Bleecker, R.P. Bowler, A.P. Comellas, C.B. Cooper, D. Couper, G.J. Criner, M.T. Dransfield, M.K. Han, N.N. Hansel, E.A. Hoffman, J.A. Krishnan, R. Paine, S.P. Peters, P.G. Woodruff, San Francisco, CA, p.A5631 202 Nationwide Trends in Ventilatory Support for COPD Exacerbations and the Markers of Increased Risk for Mortality/ A. Attaway, J. Zein, K. Alshabani, U. Majumdar, X. Wang, X. Han, U.S. Hatipoglu, Cleveland, OH, p.A5632 203 Factors Capturing the Covariance Structure of COPD Related Change Over Time Separate Change in Pulmonary Function from Change on CT Measures in COPDGene/ G.L. Kinney, K. Young, M. Ragland, M. Strand, E.A. Regan, B.J. Make, J.D. Crapo, J.E. Hokanson, Aurora, CO, p.A5633 204 Pulmonary Subtypes Are Associated with Progression from Normal Spirometry to PRISm and GOLD 1 in COPDGene/ K. Young, G.L. Kinney, M.F. Ragland, M.J. Strand, E.A. Regan, B.J. Make, J.D. Crapo, J.E. Hokanson, Aurora, CO, p.A5634 205 Deep Learning Classification of Emphysema Pattern on CT Is Associated with Progression of COPD at Five Year Followup/ S.M. Humphries, A.M. Notary, J.P. Centeo, B. El Kaddouri, D.A. Lynch, Denver, CO, p.A5635 206 The COPD-2-HOME Score: A Novel Tool to Predict Re-Exacerbation in the 90 Days Following Hospitalisation with an Acute Exacerbation of COPD (AECOPD)/ B. Cushen, G. Greene, E. MacHale, L. Tompkins, F. Boland, C. Mouronte-Roibás, J.A. Fernandez Villar, W. vanGeffen, E. Kelly, R.W. Costello, Dublin, Ireland, p.A5636 207 Novel Predictors of Outcome in Patients with COPD Associated Pulmonary Hypertension/ M. Fini, S. Pugliese, A. D’Alessandro, E.C. Dempsey, R.P. Bowler, T.M. Bull, K.R. Stenmark, Aurora, CO, p.A5637 208 Comparison of ZZ- and SZ-Genotype Patients in a Canadian Alpha-1 Antitrypsin Deficiency Population Based on the Rate of FEV1 Decline and other Clinical Characteristics/ S. Gurupatham, S. Mohan, K.R. Chapman, Toronto, Canada, p.A5638 209 A Spirometric Model of Residual Volume Predicts Outcomes in Lung Volume Reduction Surgery/ C. Riley, J. Evankovich, C.M. Karoleski, S.M. Nouraie, F.C. Sciurba, Pittsburgh, PA, p.A5639 210 Endotrophin in Combination with Von Willebrand Factor Is Predictive for Mortality in the Eclipse COPD Cohort/ N.S. Gudmann, S.R. Ronnow, L. Langholm, M. Karsdal, T. Manon-Jensen, R. Tal-Singer, B. Miller, J. Vestbo, J.M.B. Sand, D.J. Leeming, Herlev, Denmark, p.A5640 211 End Products of Fibrinogen Are Elevated in Symptomatic Chronic Obstructive Pulmonary Disease and Are Predictive of Mortality in the Eclipse Cohort/ N.S. Gudmann, T. Manon-Jensen, L. Langholm, S.R. Ronnow, R. Tal-Singer, J. Vestbo, J.M.B. Sand, D.J. Leeming, M. Karsdal, B. Miller, Herlev, Denmark, p.A5641 212 Validation of Individualized Prediction of Lung Function Decline in Patients Diagnosed with COPD/ M. Kerkhof, J. Voorham, C. Cabrera, P. Darken, P. Dorinsky, J.W.H. Kocks, M. Sadatsafavi, D.D. Sin, D.B. Price, Singapore, Singapore, p.A5642 213 PROMIS-29 Scores Associated with Longitudinal Changes in Cough and Phlegm Severity in Patients with COPD Within the Chronic Obstructive Pulmonary Disease Patient-Powered Research Network (COPD PPRN)/ R. Choate, C.B. Pasquale, N.A. Parada, V. Prieto-Centurion, B.P. Yawn, Lexington, KY, p.A5643 214 Identification of Subtypes Predicting Exacerbations in COPD Using Cluster Analysis/ J.H. Lee, H.-Y. Yoon, S.H. Lee, S.J. Kim, Y.J. Ryu, J.H. Chang, C.K. Rhee, K.H. Yoo, K.-S. Jung, Seoul, Korea, Republic of, p.A5644 215 Impact of Bronchiectasis on Clinical Outcome and Medical Utilization in Chronic Obstructive Pulmonary Disease Patients/ Y. Kim, K. Kim, S.W. Ra, C.K. Rhee, Chuncheon-si, Korea, Republic of, p.A5645 216 Longitudinal Evaluation of Self-Reported Gastroesophageal Reflux Disease (GERD) and Lung Function Decline in the COPDGene Cohort/ A.K. Baldomero, A. Petersen, N. Gaeckle, M.K. Han, K.M. Kunisaki, C.H. Wendt, Minneapolis, MN, p.A5646 ATS 2019 • Dallas, TX TUESDAY • MAY 21 301 TUESDAY AFTERNOON